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Int roduct ion 
Lysosoma l e l a s tase f rom p o l y m o r p h o n u c l e a r (PMN) g r a n u l o c y t e s is b e l i e v e d t o 
be an i m p o r t a n t nonspec i f i c m e d i a t o r o f i n f l a m m a t i o n c o n t r i b u t i n g t o t h e 
d e v e l o p m e n t o f s e p s i s - and t r a u m a - r e l a t e d o r gan f a i l u r e [1 ] . We h a v e f o u n d 
p r e v i o u s l y t h a t a lso t h e l y sosoma l c y s t e i n e p r o t e i n a s e (CP) c a t h e p s i n Β or a 
c a t h e p s i n B - l i k e enzyme is r e l eased i n t o t h e b lood p l a s m a o f p a t i e n t s d u r i n g 
s ep t i c shock [21. I n c o n t r a s t t o PMN e l a s t a s e , r e l e a s e d c a t h e p s i n Β can be 
d e t e c t e d by i t s enzymat i c a c t i v i t y because i t i s o n l y l o o s e l y b o u n d t o t h e 
p lasma i n h i b i t o r s and d i s soc i a t e s r e a d i l y u p o n d i l u t i o n . 
Here we w a n t t o r e p o r t f u r t h e r e v i d e n c e f o r t h e r e l ease o f c y s t e i n e p r o t e i n ­
ases i n t o t h e c i r c u l a t i o n of p o l y t r a u m a t i z e d p a t i e n t s a n d , l o c a l l y , i n t o t h e 
a l v e o l a r e p i t h e l i a l l i n i n g f l u i d a n d p u r u l e n t p e r i t o n e a l e x u d a t e s . I n c r e a s e d 
c y s t e i n e p r o t e i n a s e a c t i v i t y was a lso o b s e r v e d i n t h e b l o od p l asma o f p i gs 
sub j e c t ed t o e x p e r i m e n t a l s ep t i c shock . I n a l l cases t h e re l eased c y s t e i n e 
p r o t e i n a s e a c t i v i t y was i d e n t i f i e d as t h a t o f c a t h e p s i n Β o r a c a t h e p s i n B -
l i k e enzyme. I t s i n t e r a c t i o n w i t h t h e p l a sma c y s t e i n e p r o t e i n a s e i n h i b i t o r s 
was i n v e s t i g a t e d i n v i t r o u s i n g samples f r om i n d i v i d u a l p a t i e n t s . I n d i r e c t 
e v i d ence w i l l be p r o v i d e d t h a t t h e m a i n p o r t i o n o f t h e r e l eased l y s o s o m a l 
c y s t e i n e p r o t e inase ( s ) s h o u l d o r i g i n a t e f r o m ce l l s o t h e r s t h a n PMN g r a n u l o ­
cy t es , most p r o b a b l y f rom macrophages , a n d may p l a y a ro l e as n o n s p e c i f i c 
m e d i a t o r ( s ) o f i n f l a m m a t i o n . 
Enzymes: 
C a t h e p s i n Β (EC 3.4 .22.1 ) ; C a t h e p s i n Η (3 .4 .22 .16 ) ; C a t h e p s i n L ( 3 .4 .22 .15 ) ; 
L e u k o c y t e e las tase (EC 3.4 .21.37) . 
Abbreviations: 
012M, a 2 - m a c r o g l o b u l i n ; (XiPI, α ι -p ro t e inase i n h i b i t o r ; ARDS, a d u l t r e s p i r a t o r y 
d i s t r e s s syndrome; BALF, b r o n c h o a l v e o l a r l a v a g e f l u i d ; CP, c y s t e i n e 
p r o t e i n a s e ( s ) ; ELISA, e n z y m e - l i n k e d i m m u n o s o r b e n t assay ; E - 6 4 , l-(trans-
e p o x y s u c c i n y l - L - l e u c y l a m i n o ) - 4 - g u a n i d i n o b u t a n e ; FPLC, f a s t p r o t e i n l i q u i d 
c h r o m a t o g r a p h y ; NMec, ( 4 - m e t h y l - 7 - c o u m a r y l ) a m i d e ; PMN, p o l y m o r p h o n u c l e a r ; 
SEM, s t a n d a r d e r r o r o f t h e mean; Z, b e n z y l o x y c a r b o n y l . 
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Mater ia l s and Methods 
Patients and samples 
D e t a i l s a b o u t t h e o r g a n i z a t i o n o f t h e c l i n i c a l s tud i e s and samp l i ng p r o t o c o l s 
are p r o v i d e d i n r e f . [3] f o r p o l y t r a u m a t i z e d p a t i e n t s , i n re f . [4] f o r BALF and 
i n r e f . [5 ,6 ] f o r p e r i t o n i t i s e x u d a t e s . E x p e r i m e n t a l s ep t i c shock i n anes t e s i z ed 
p igs was p e r f o r m e d as d e s c r i b e d [7J. A l l samples were s t o r e d f r o z en and 
t h a w e d o n l y once i m m e d i a t e l y be fore d e t e r m i n a t i o n . 
Separation and lysis of blood cells 
H e p a r i n i z e d h u m a n b l o o d , d i l u t e d w i t h t i s s u e c u l t u r e med ium RPMI 1640 
(Gibco) was l a y e r e d o v e r l y m p h o c y t e s e p a r a t i o n medium MSL ( d = 1.077, E u r o b i o ) 
and c e n t r i f u g e d . T h e m o n o n u c l e a r c e l l s were r e c e n t r i f u g e d i n RPMI and l y s e d 
i n 50 mM s o d i u m a c e t a t e b u f f e r pH 5.5 c o n t a i n i n g 0.5 % T r i t o n X - 1 0 0 , 0.3 mM 
EDTA a n d 0 .01 % B r i j 35 . For p r e p a r a t i o n o f PMN g r a n u l o c y t e s M o n o - P o l y 
R e s o l v i n g Med ium ( F l ow ) was used . 
Assay for cysteine proteinase activity 
CP a c t i v i t y was m e a s u r e d i n c o n t i n u o u s assays w i t h t h e f l uo r ogen i c s u b s t r a t e s 
Z - P h e - A r g - N M e c , Z - A r g - A r g - N M e c a n d A r g - N M e c u s i n g the spec i f i c i n h i b i t o r 
E - 6 4 as d e s c r i b e d [ 2 ] . 
Stopped assay for papain inhibiting capacity 
I n c r e a s i n g v o l u m e s o f sample d i l u t i o n s were i n c u b a t e d w i t h p a p a i n (7 nM) i n 
a c e t a t e b u f f e r pH 5.5, 1 mM d i t h i o t h r e i t o l , 2 mM EDTA, 0.015 % Br i j 35, f o r 
25 m i n a t 30 °C. A f t e r d i l u t i o n t h e s u b s t r a t e Z - P h e - A r g - N M e c (10 μΜ) was 
added a n d t h e r e a c t i o n was s t opped w i t h monoch l o r oac e t a t e a f t e r 1 5 - 2 5 m i n . 
ELISA for human cathepsin Β 
I m m u n o s e l e c t e d p o l y c l o n a l a n t i b o d i e s a g a i n s t h u m a n c a t h e p s i n Β were p r epa r ed 
f r om sheep a n t i s e r u m w i t h c a t h e p s i n Β immob i l i z ed on C N B r - a c t i v a t e d 
Sepharose . C a t h e p s i n Β b o u n d t o m i c r o t i t e r p l a t e s coated w i t h t h e a n t i b o d i e s 
was d e t e r m i n e d i n a s a n d w i c h ELISA u s i n g b i o t i n y l a t e d a n t i b o d i e s and b i o t i n -
a v i d i n - p e r o x i d a s e f o r d e t e c t i o n . 
ELISA for human elastase 
G r a n u l o c y t i c e l a s t a s e was e s t i m a t e d i n complex w i t h a i - p r o t e i n a s e i n h i b i t o r 
a c c o r d i n g t o r e f . [5 ] u s i n g a spec i f i c t w o - s i t e ELISA. 
Gel chromatography 
S e p a r a t i o n o f p a t i e n t p l a s m a on a Superose 12 FPLC co lumn was per fo rmed as 
d e s c r i b e d [ 2 ] . I n h i b i t o r y a c t i v i t y o f t h e i n d i v i d u a l f r a c t i o n s was d e t e r m i n e d i n 
s t o p p e d a s says as a b o v e u s i n g 1/40 o f each f r a c t i o n (0.4 ml ) w i t h 200 pM 
p a p a i n . 
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R e s u l t s 
CP a c t i v i t y in blood plasma of poly t raumat i zed p a t i e n t s 
CP a c t i v i t y o f b lood p lasma was f o l l o w e d i n 69 i n t e n s i v e ca r e p a t i e n t s due to 
s e v e r e t r a u m a w i t h a mean i n j u r y s e v e r i t y score (1SS) a c c o r d i n g t o B a k e r e t 
a l . [8] o f 36 (see [3] f o r d e t a i l s ) . W i t h i n 6 h a f t e r t h e i n j u r y , i n c r e a s e d l e v e l s 
o f CP a c t i v i t y ( mean: 5 - 6 - f o l d o f n o r m a l ) were f o u n d i n t h e b l o o d p l a sma 
o f p a t i e n t s who deve l oped l e t h a l ( F i g . 1 A) or r e v e r s i b l e ( F i g . 1 B) m u l t i p l e 
o r g a n f a i l u r e s e ve ra l days l a t e r . I n i t i a l CP a c t i v i t y was s i g n i f i c a n t l y l owe r 
(mean : 3 - f o l d o f no rma l ) i n p o l y t r a u m a t i z e d p a t i e n t s w i t h o u t s u b s e q u e n t o r gan 
f a i l u r e (F i g . 1 C). In a l l t h r e e g roups CP a c t i v i t y r e a c h e d i t s m a x i m u m 6 h 
be fo re c u P I - b o u n d PMN e las tase , and r e t u r n e d t o v a l u e s a b o u t 2 - f o l d o f t h e 
n o r m a l w i t h i n 3 days . 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 Η 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Η 
Time [d] Time [d] 
15 -| 1 1 1 1 1 1 1 I 1 1 I I L 
0 Η 1 1 1 1 1 1 1 1 1 1 1 1 1 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Time [dj 
Fig . 1. Catheps in Β a c t i v i t y and αιΡΙ-bound e l a s t a s e l e v e l s in blood p lasma 
of polytraumatized pat ients expressed as the mul t ip le of normal v a l u e s (50 
mU/1 f o r c a t h e p s i n B, 90 ng/ml f o r e l a s t a s e ) . A, p a t i e n t s w i t h l e t h a l o r g a n 
f a i l u r e ( n = l l ) ; B, p a t i e n t s w i t h r e v e r s i b l e o r gan f a i l u r e ( n = 2 9 ) ; C, p a t i e n t s 
w i t h o u t o rgan comp l i c a t i ons ( n = 2 9 ) . 
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As r e p o r t e d p r e v i o u s l y [2 ] , d i l u t i o n e x p e r i m e n t s r e v e a l e d t h a t t h e C P - a c t i v i t y 
o f b lood p lasma is i n e q u i l i b r i u m w i t h r e v e r s i b l e c y s t e i n e p r o t e i n a s e 
i n h i b i t o r s . E v a l u a t i o n o f d i l u t i o n e x p e r i m e n t s p e r f o r m e d w i t h p l a s m a o f 
i n d i v i d u a l p o l y t r a u m a t i z e d p a t i e n t s (F i g . 2) p r o v i d e d e s t i m a t e s o f Km = 98 μΜ 
and It/Κι = 1 5 - 2 0 (Km, M i chae l i s c o n s t a n t ; I t , t o t a l i n h i b i t o r c o n c e n t r a t i o n ; 
K i , i n h i b i t i o n c o n s t a n t ) . The r o u t i n e assay used i n t h e c l i n i c a l s t u d i e s w i t h 
p o l y t r a u m a t i z e d p a t i e n t s (80 μ] P lasma i n 1.5 ml t o t a l v o l u m e , 150 μΜ 
s u b s t r a t e ) d e t e c t s app rox . 60 % o f t o t a l C P - a c t i v i t y as f r ee , a c t i v e enzyme . 
CP a c t i v i t y i n bronchoa lveo lar l avage f lu id 
One o f t h e f a t a l c o m p l i c a t i o n s o f p o l y t r a u m a t i z e d p a t i e n t s i s t h e a d u l t 
r e s p i r a t o r y d i s t r e s s syndrome (ARDS). We f o u n d t h a t b r o n c h o a l v e o l a r l a vage 
f l u i d (BALF) o f a p a t i e n t w i t h ARDS c o n t a i n e d h i g h l e v e l s o f CP a c t i v i t y 
compared t o t h a t o f a p o l y t r a u m a t i z e d p a t i e n t w i t h o u t t h i s c o m p l i c a t i o n (F ig . 
3 ) . For c ompar i s on w i t h PMN e l as tase , t h e CP a c t i v i t y was c o n v e r t e d i n t o 
ng/ml c a t h e p s i n Β assuming a spec i f i c a c t i v i t y o f 80 ü/mg f o r p u r i f i e d 
c a t h e p s i n Β [21. The m a x i m a l l e v e l s o f α ιΡ Ι -bound e l a s t a s e were a p p r o x . 2 0 -
f o l d h i g h e r t h a n those o f c a t h e p s i n Β a n d d i d n o t a l w a y s c o i n c i d e w i t h t h e 
l a t t e r . I n some samples an e l a s t a s e / c a t h e p s i n Β r a t i o c lose t o 1.0 was 
obse r v ed . 
C a t h e p s i n Β c o n c e n t r a t i o n s measured w i t h an ELISA u s i n g spe c i f i c a n t i b o d i e s 
a g a i n s t h u m a n l y sosoma l c a t h e p s i n Β c o r r e l a t e d w e l l w i t h t h e c o n c e n t r a t i o n s 
c a l c u l a t e d f r o m a c i t i v i t y (Tab le 1). These r e s u l t s i n d i c a t e t h a t , i n t h i s 
p a t i e n t , v i r t u a l l y a l l measured c y s t e i n e p r o t e i n a s e a c t i v i t y was due to 
c a t h e p s i n Β (or a c r o s s - r e a c t i v e p roenzyme ) a n d most o f t h e i m m u n o l o g i c a l l y 
d e t e c t a b l e enzyme was e n z y m a t i c a l l y a c t i v e . T i t r a t i o n o f p a p a i n w i t h BALF 
r e v e a l e d t h e absence o f c y s t e i n e p r o t e i n a s e i n h i b i t o r s ( l ess t h a n 10 nM 
compared to 5 μΜ i n n o r m a l p lasma) and no d i s s o c i a t i o n was o b s e r v e d i n 
d i l u t i o n e x p e r i m e n t s . 
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Fig . 2. D i lut ion a n a l y s i s of CP a c t i v i t y in blood p lasma of a po lyt raumat ized 
pat ient . F rom a r e p l o t a c c o r d i n g t o D i x o n [9} ( l owe r pane l ) Km was e s t i m a t e d 
as 98 μΜ and a I t / K i o f 16 was c a l c u l a t e d f o r c o m p e t i t i v e i n h i b i t i o n (Km, 
Michae l i s c o n s t a n t ; I t , t o t a l i n h i b i t o r c o n c e n t r a t i o n ; K i , i n h i b i t i o n c o n s t a n t ) . 
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F i g . 3. L e v e l s of c a t h e p s i n Β ( f i l led c i r c l e s ) and αιΡΙ-bound e l a s t a s e (open 
c i r c l e s ) i n b ronchoa lveo la r l avage f luid of po lyt raumat ized pa t i en t s wi th ARDS 
(A) and wi thout ARDS (B). T h e c a t h e p s i n Β l e v e l was c a l c u l a t e d f r om 
e n z y m a t i c a c t i v i t y a s s u m i n g a spec i f i c a c t i v i t y o f 80 U/mg. 
T a b l e 1. C o r r e l a t i o n between CP a c t i v i t y and immuno-react ive 
c a t h e p s i n Β (ELISA ) i n BALF of a p a t i e n t w i th ARDS 
Sample 3 CP a c t i v i t y 
tmU/1] 
E n z y m a t i c a l l y 
a c t i v e 
c a t h e p s i n B b 
[ng/ml] 
Immune-reactive 
c a t h e p s i n Β 
[ng/ml] 
431/1 3 267 40 .8 39.7 
431/5 618 7.7 8.0 
431/7 9 194 114.9 121.7 
431/8 4 429 55.4 46.6 
431/10 2 232 27.9 23.6 
431/11 618 7.7 10.8 
431/12 1 622 20.3 26.2 
a see F i g . 3 f o r c o m p a r i s o n 
C a l c u l a t e d a s s u m i n g a spec i f i c a c t i v i t y o f 80 U/mg 















F i g . 4. C a t h e p s i n Β a c t i v i t y i n b l ood p l a s m a o f p i g s s u b j e c t e d t o e x p e r i m e n t a l 
e n d o t o x i n shock . 19 a n e s t e s i z e d m i n i a t u r e p igs r e c e i v e d an i . v . i n f u s i o n o f 
b a c t e r i a l l i p o p o l y s a c c h a r i d e f r o m 5. abortus equi f o r 6 h o u r s a n d d e v e l o p e d a 
s e v e r e sep t i c shock w i t h low a r t e r i a l mean p r e s s u r e ( s o l i d t r i a n g l e s ) . 
C a t h e p s i n Β a c t i v i t y i n c r e a s e d ( s o l i d c i r c l e s ) as compared t o c o n t r o l a n i m a l s 
( n = 7 ) r e c e i v i n g an NaCl i n f u s i o n (open c i r c l e s ) . D a t a are mean v a l u e s + / -
SEM. 
CP a c t i v i t y i n e x p e r i m e n t a l e n d o t o x i n shock o f p i g s 
A r e p r o d u c i b l e i n c r e a s e o f CP a c t i v i t y o f b l ood p l a sma was o b s e r v e d i n p igs 
s u b j e c t e d t o s e v e r e s e p t i c shock by i n f u s i o n o f b a c t e r i a l e n d o t o x i n . C a t h e p s i n 
Β a c t i v i t y c o r r e l a t e d w i t h p h y s i o l o g i c a l shock p a r a m e t e r s l i k e decrease o f 
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F i g . 5. C a t h e p s i n Β v e r s u s c u P I - b o u n d e l a s t a s e l e v e l s i n p e r i t o n e a l e x u d a t e s . 
C a t h e p s i n Β l e v e l s we re c a l c u l a t e d f r om e n z y m a t i c a c t i v i t y a s s u m i n g a spec i f i c 
a c t i v i t y o f 80 U/mg; c u P I - b o u n d e l as tase was d e t e r m i n e d by ELISA [5 ] . Open 
c i r c l e s , c l ea r e x u d a t e s ( n = 9 ) ; s o l i d c i r c l e s , a c u t e p e r i t o n i t i s ( n = 9 ) ; s o l i d 
s q u a r e s , p e r s i s t e n t p e r i t o n i t i s t r e a t e d by E t a p p e n l a v a g e ( n = 9 ) ; s o l i d t r i a n g l e s , 
p a n c r e a t i t i s ( n = 2 ) . 
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CP a c t i v i t y in pe r i tonea l e xuda te s 
P e r i t o n i t i s e x u d a t e s c o n t a i n h i g h l e v e l s o f o t i P I - b o u n d a n d e v e n f ree e l a s t a s e 
w h i c h i s b e l i e v e d t o c o n t r i b u t e t o n o n s p e c i f i c p r o t e o l y t i c b r e a k d o w n o f 
o p s o n i n s l i k e C3 and IgG r e s u l t i n g i n d i m i n i s h e d o p s o n i z i n g a c t i v i t y [5) . We 
f o u n d a l so h i g h l e v e l s o f CP a c t i v i t y i n most o f t h e s e e x u d a t e s (F i g . 5, Tab l e 
2 ) . CP a c t i v i t y d i d n o t a l w a y s p a r a l l e l o u P I - b o u n d e l a s t a s e . H i g h CP a c t i v i t y 
a n d m o d e r a t e e l a s t a s e l e v e l s were f o u n d i n cases o f a c u t e p e r i t o n i t i s whereas 
b o t h CP a c t i v i t y a n d e l a s t a s e c o n c e n t r a t i o n t e n d e d t o be e x t r e m e l y e l e v a t e d 
i n p a t i e n t s w i t h p e r s i s t e n t p u r u l e n t p e r i t o n i t i s t r e a t e d b y E t a p p e n l a v a g e [6 ] . 
CP a c t i v i t y a n d e l a s t a s e were low i n c l e a r e x u d a t e s . 
L i k e i n p l a sma , CP a c t i v i t y i n p e r i t o n e a l e x u d a t e s d i s s o c i a t e s r e v e r s i b l y f r om 
c o m p l e x e s u p o n d i l u t i o n . T y p i c a l Km a n d It/Κι were d e t e r m i n e d as 150 μΜ and 
5 0 , r e s p e c t i v e l y . 
T a b l e 2 . E l a s t a s e and c a t h e p s i n Β i n p e r i t o n e a l exudates 
Samples E l a s t a s e C a t h e p s i n Β E l a s t a s e / 
mean mean c a t h e p s i n Β 
± SEM ± SEM 
[ng/ml] [ng/ml a ] 
C l e a r exudates 1 502 ± 848 30 ± 14 49 
(n = 9) 
Acute p e r i t o n i t i s 13 809 ± 5 584 146 ± 58 95 
(n = 9) 
Etappen lavage 74 900 ± 13 219 198 + 62 378 
(η = 9) 
C a l c u l a t e d f r om e n z y m a t i c a c t i v i t y a s s u m i n g a s p e c i f i c a c t i v i t y 
o f 80 U/mg 
CP a c t i v i t y of blood monocytes and g ranu locytes 
Lysed i s o l a t e d g r a n u l o c y t e s (98 % o f t o t a l c e l l s ) f r o m n o r m a l p e r i p h e r a l b l o od 
were f o u n d t o h a v e a low b u t s i g n i f i c a n t CP a c t i v i t y o f 115 rnU/10 6 c e l l s 
c o r r e s p o n d i n g t o 1.4 ng/10 6 c e l l s o f c a t h e p s i n B. 1 0 - 2 0 - f o l d h i g h e r CP 
a c t i v i t y was f o u n d i n l y s a t e s o f a f r a c t i o n c o n t a i n i n g 14.5 % monocy t e s , 83.9 
% l y m p h o c y t e s and o n l y 0.16 % g r a n u l o c y t e s . 
Subs t r a t e spec i f i c i t y of CP a c t i v i t y 
The s p e c i f i c i t y o f CP a c t i v i t y i n b l o od p l asma , BALF and p e r i t o n e a l e x u d a t e s 
f o r s m a l l s y n t h e t i c p e p t i d e s u b s t r a t e s c l o s e l y r e semb l es t h a t o f i s o l a t e d 
h u m a n c a t h e p s i n Β ( Tab l e 3 ) . As j u d g e d f r o m a c t i v i t y w i t h t h e a m i n o p e p t i d a s e 
s u b s t r a t e A r g - N M e c , less t h a n 1 % o f t h e e n d o p e p t i d a s e a c t i v i t y w i t h Z - P h e -
A r g - N M e c can be a t t r i b u t e d t o c a t h e p s i n H . Because o f t h e low spec i f i c 
a c t i v i t y o f c a t h e p s i n Η (1.5 U/mg as c a l c u l a t e d f r o m k c a t a n d Km i n re f . [ 11 ] , 
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i t s p resence i n a p p r e c i a b l e a m o u n t s c a n n o t be e x c l u d e d . A s i g n i f i c a n t 
c o n t r i b u t i o n o f c a t h e p s i n L ( spec i f i c a c t i v i t y 36 U/mg w i t h Z - P h e - A r g - N M e c 
a c c o r d i n g t o re f . [ 1 2 ] , h o w e v e r , is r u l e d o u t b y t h e e s t i m a t e d Km v a l u e s (see 
Tab l e 3) a n d t h e o b s e r v e d It/Κι (see D i s c u s s i o n ) . 
Table 3 . S u b s t r a t e s p e c i f i c i t y of CP a c t i v i t y 
Sample R a t i o of a c t i v i t i e s Km 
wi th (μΜ) 3 
Z--Arg-Arg-NMec/ R-NMec/ 
Z--Phe-Arg-NMec Z--Phe-Arg-NMec 
[145 μΜ] [56 μΜ] 
I s o l a t e d l y so soma l 
c a t h e p s i n Η 17 
c a t h e p s i n L < 0 .0002 2 . 4 b 
c a t h e p s i n Β 0 .22 < 0 .00005 160 c 
Human monocytes' 1 0.20 n . d . n . d . 
Human g r anu l ocy t e s ' 1 0.19 n . d . n . d . 
P e r i t o n i t i s exudate 0 .19 0 .014 150 
BALF ( p a t i e n t w i t h ARDS) 0 .12 0 .006 225 
Plasma (polytrauma) 0 .07 0 .04 95 
Plasma ( s e p s i s ) 0 .22 0 .08 170 c 
a w i t h Z - P h e - A r g - N M e c , d e t e r m i n e d f r om d i l u t i o n e x p e r i m e n t s 
un l ess o t h e r w i s e i n d i c a t e d 
b f r o m re f . [12] 
c f r o m r e f . [ 2 ] 
d f r o m l y s a t e s o f i s o l a t e d ce l l s o f n o r m a l p e r i p h e r a l b l ood 
Endogenous inh ib i to r s of c y s t e i n e prote inases 
The i n h i b i t o r y c a p a c i t y f o r CP was d e t e r m i n e d by t i t r a t i o n o f a c o n s t a n t 
a m o u n t o f p a p a i n w i t h i n c r e a s i n g a m o u n t s o f samples (p lasma, e x u d a t e , BALF ) 
f r om i n d i v i d u a l p a t i e n t s . E q u i v a l e n c e was assumed w h e n a c o n s t a n t e n z y m a t i c 
a c t i v i t y was r e a ched . T h i s c o n s t a n t a c t i v i t y i s due t o p a p a i n e n t r a p p e d i n 
CX2M w h e r e i t r e m a i n s s t i l l a c t i v e a g a i n s t t h e s m a l l s y n t h e t i c s u b s t r a t e [ 13 ] . 
The r e m a i n i n g a c t i v i t y ( 1 0 - 4 0 % ) was s u b t r a c t e d f r o m t h e i n i t i a l a c t i v i t y o f 
p a p a i n . The p a p a i n i n h i b i t i n g c a p a c i t y o f n o r m a l b l o od p l asma is a r o u n d 5 μΜ. 
Reduced i n h i b i t o r y c a p a c i t y was f o u n d i n p l asma samples o f some 
p o l y t r a u m a t i z e d p a t i e n t s . B A L F c o n t a i n e d less t h a n 10 nM f ree i n h i b i t o r s 
(Tab le 4 ) . 
C h r o m a t o g r a p h y o f p l a s m a f r o m a p o l y t r a u m a t i z e d p a t i e n t on a Superose 12 
FPLC c o l u m n s e p a r a t e d t w o m a i n peaks o f i n h i b i t o r y a c t i v i t y c o r r e s p o n d i n g t o 
m o l e c u l a r masses o f 70 k D a a n d 15 kDa , r e s p e c t i v e l y ( d a t a n o t s h o w n ) . Weak 
i n h i b i t i o n o f p a p a i n a c t i v i t y was a lso f o u n d i n t h e h i g h m o l e c u l a r mass r e g i o n 
where c t 2 M is e l u t e d . 
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T a b l e 4 . I n h i b i t o r y c a p a c i t y for papa in 
Sample I n h i b i t o r y c a p a c i t y N o n - t i t r a b l e 
f o r p a p a i n a c t i v i t y 
[ u m o l / l ] [% o f t o t a l ] 
No rma l p lasma (n=2) 4 . 2 - 5 .6 23 - 29 
P o l y t r a u m a p lasma (n=15) 1.4 - 5 .6 14 - 26 
P e r i t o n e a l e x u d a t e (n=6) 0 .6 - 2 .5 9 - 14 
BALF (n=3) < 0 . 0 1 n . d . 
D i s c u s s i o n 
Nature and c e l l u l a r or ig in of r e l eased CP a c t i v i t y 
T h e p r e s e n t e d r e s u l t s o f a c l i n i c a l s t u d y w i t h p o l y t r a u m a t i z e d p a t i e n t s 
c o n f i r m e d and e x t e n d e d p r e v i o u s o b s e r v a t i o n s t h a t , b es ides t h e l y s o s o m a l 
s e r i n e p r o t e i n a s e s PMN e l a s t a s e a n d c a t h e p s i n G, a l so c y s t e i n e p r o t e i n a s e s 
a re r e l e a s e d i n t o t h e c i r c u l a t i o n u n d e r c o n d i t i o n s o f s e v e r e t r a u m a and 
i n f l a m m a t i o n . H i g h l e v e l s o f t h i s e n z y m a t i c a c t i v i t y we re d e t e c t e d l o c a l l y i n 
b r o n c h o a l v e o l a r l a v a g e f l u i d and p e r i t o n e a l e x u d a t e s . As i n p r e v i o u s wo rk , 
t h e s p e c i f i c i t y o f o u r assay f o r t h i s c lass o f p r o t e i n a s e s was e n s u r e d by t h e 
use o f t h e spec i f i c a c t i v e - s i t e i n a c t i v a t o r E - 6 4 [ 14 ] . A c t i v i t y measuremen ts 
u s i n g d i f f e r e n t p e p t i d e s u b s t r a t e s a n d Km d e t e r m i n a t i o n s f r o m D i x o n p l o t s 
(see T a b l e 3) i n d i c a t e d t h a t t h e e n z y m a t i c a c t i v i t y o f a l l s t u d i e d samples 
s h o u l d be m a i n l y due t o c a t h e p s i n Β or a c a t h e p s i n B - l i k e enzyme. I n t h e 
case o f BALF t h i s was d i r e c t l y c o n f i r m e d w i t h a s p e c i f i c ELISA fo r h u m a n 
c a t h e p s i n B. 
T h o u g h Z - A r g - A r g - N M e c w o u l d be more spec i f i c f o r c a t h e p s i n Β (cf. Tab l e 3 ) , 
Z - P h e - A r g - N M e c has been se l e c t ed f o r r o u t i n e assay , because t h i s s u b s t r a t e 
i s 4 t i m e s more s e n s i t i v e f o r c a t h e p s i n B - l i k e a c t i v i t y a n d l ess s e n s i t i v e to 
E - 6 4 - r e s i s t a n t n o n - c y s t e i n e p r o t e i n a s e a c t i v i t y f o u n d i n some samples [2|. 
I n b l ood p l a sma as w e l l as i n l o c a l s e c r e t i o n s t h e o b s e r v e d c a t h e p s i n B - l i k e 
a c t i v i t y c o r r e l a t e s w i t h t h e seve reness o f t h e c l i n i c a l m a n i f e s t a t i o n o f o r gan 
d y s f u n c t i o n s . H i gh c a t h e p s i n Β a c t i v i t y o f b l ood p l a s m a d e t e c t a b l e soon a f t e r 
t h e t r a u m a t i c e v e n t seems t o be a s e n s i t i v e and s p e c i f i c p a r a m e t e r f o r t h e 
p r e d i c t i o n o f t r a u m a - r e l a t e d o r gan f a i l u r e (see r e f . [3] f o r d e t a i l s ) . 
As we h a v e c o n f i r m e d i n t h i s w o r k , PMN g r a n u l o c y t e s o f n o r m a l b l ood c o n t a i n 
o n l y m i n o r a m o u n t s o f c a t h e p s i n Β (1.5 ng/10 6 c e l l s ) , c o m p a r e d t o 5 - 9 u g / l o 6 
c e l l s o f e l a s t a s e [ 15 ] . The r a t i o o f c e l l u l a r e l a s t a s e / c a t h e p s i n Β c o n t e n t 
( 3 0 0 0 - 6 0 0 0 ) i s r o u g h l y 1 0 - 3 0 - f o l d h i g h e r t h a n t h e r a t i o o f r e l eased 
e l a s t a s e / c a t h e p s i n Β i n b l ood p lasma o f p o l y t r a u m a p a t i e n t s ( 2 0 0 - 3 0 0 ) and 
i n p e r i t o n i t i s e x u d a t e s ( 1 0 0 - 4 0 0 ) . T h e r e f o r e s i m u l t a n e o u s r e l ease o f b o t h 
enzymes f r o m PMN g r a n u l o c y t e s can p r o b a b l y n o t a c c o u n t f o r t h e obse r ved 
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c a t h e p s i n Β l e v e l s . M e a s u r e m e n t o f i n t r a c e l l u l a r c a t h e p s i n Β a c t i v i t y b y f l ow 
c y t o m e t r y i n d i c a t e d , h o w e v e r , t h a t PMN g r a n u l o c y t e s may inc r ease t h e i r 
c a t h e p s i n Β c o n t e n t u n d e r i n f l a m m a t o r y c o n d i t i o n s (G. Rothe and G. V a l e t , 
u n p u b l i s h e d r e s u l t s ) . Moreove r , i n p e r i t o n e a l e x u d a t e s , a c o n t r i b u t i o n o f 
b a c t e r i a l c y s t e i n e p r o t e i n a s e s has t o be c o n s i d e r e d . 
A n e l a s t a s e / c a t h e p s i n Β r a t i o c lose t o 1.0 was f o u n d i n BALF w h i c h is k n o w n 
t o c o n t a i n l a r g e n u m b e r s o f a l v e o l a r macrophages [ 16 ] . A c c o r d i n g t o t h e 
c e l l u l a r c o n t e n t s [ 1 7 , 1 8 ] , macrophages m u s t be c o n s i d e r e d as a m a i n source 
f o r r e l e a s e d c a t h e p s i n B. I n c e l l l y s a t e s , m o n o c y t e s o f n o r m a l p e r i p h e r a l b l ood 
c o n t a i n 1 0 - 2 0 t i m e s more c a t h e p s i n Β a c t i v i t y t h a n g r a n u l o c y t e s . Recen t l y , a 
s e n s i t i v e f l o w c y t o m e t r i c a ssay f o r i n t r a c e l l u l a r c a t h e p s i n Β a c t i v i t y has been 
d e v e l o p e d (G. Ro the e t a l . , u n p u b l i s h e d ) . Us ing t h i s assay , a 5 5 - f o l d h i g h e r 
c a t h e p s i n Β a c t i v i t y was d e t e c t e d i n l i v i n g h u m a n monocy t e s as compared t o 
n e u t r o p h i l s . T h e 5 - f o l d h i g h e r c y t o m e t r i c r esponse o f t h i o g l y c o l a t e - e l i c i t e d 
r a t p e r i t o n e a l m a c r o p h a g e s i n c ompar i s on t o r e s i d e n t p e r i t o n e a l macrophages 
sugges t s t h a t c a t h e p s i n Β a c t i v i t y i s i n d e e d a c e l l u l a r m a r k e r f o r a c t i v a t i o n 
a n d d i f f e r e n t i a t i o n o f mac rophages . I n b l o o d p l a sma a n d s e c r e t i ons , i n c r eased 
c a t h e p s i n Β a c t i v i t y a c compan i ed b y an decreased e l a s t a s e / c a t h e p s i n Β r a t i o 
may t u r n o u t t o be a n e x t r a c e l l u l a r p l a s m a t i c m a r k e r f o r macrophage 
a c t i v a t i o n . 
I n t e r a c t i o n of CP a c t i v i t y w i t h endogenous prote in inh ib i to r s 
P a p a i n , a p l a n t c y s t e i n e p r o t e i n a s e , was used t o d e t e r m i n e t h e i n h i b i t o r y 
c a p a c i t y f o r c y s t e i n e p r o t e i n a s e s , because t h i s enzyme is v e r y s i m i l a r t o 
l y s o s o m a l c a t h e p s i n L. B o t h p r o t e i n a s e s b i n d t i g h t l y t o a l l k n o w n c y s t e i n e 
p r o t e i n a s e i n h i b i t o r s o f b l o o d a n d t i s s u e s [19 ] . A c c o r d i n g t o t h e r e s u l t s o f t h e 
p a p a i n assay , b l o o d p l a s m a a n d p e r i t o n e a l e x u d a t e c o n t a i n a h i g h i n h i b i t o r y 
c a p a c i t y f o r c y s t e i n e p r o t e i n a s e s . The i n h i b i t o r y c a p a c i t y o f b lood p lasma was 
f o u n d t o be r e d u c e d t o a b o u t 30 % i n some p o l y t r a u m a p a t i e n t s . I t r e t u r n s t o 
n o r m a l o r s l i g h t l y r e d u c e d v a l u e s w i t h i n t w o weeks . 
D i x o n p l o t a n a l y s i s o f p l a s m a samples f r o m i n d i v i d u a l p a t i e n t s (see F i g . 2) 
p r o v i d e d e s t i m a t e s o f t h e r a t i o It/Κι. A r a t i o o f 20 f o u n d i n p lasma o f 
p o l y t r a u m a t i z e d p a t i e n t s p o i n t s t o t h e k i n i n o g e n s ( e xpec t ed It/Κι = 8 - 1 6 0 ) 
a n d c y s t a t i n C ( e x p e c t e d It/Κι = 5 0 - 1 2 0 ) as t h e most i m p o r t a n t i n h i b i t o r s 
i n v o l v e d i n t h e e q u i l i b r i u m w i t h c a t h e p s i n Β [2 ] . T h i s i s c o n s i s t e n t w i t h t h e 
m o l e c u l a r masses o f t h e obse r v ed i n h i b i t o r y f r a c t i o n s i n b lood p lasma. 
C a t h e p s i n L i s b o u n d t o k i n i n o g e n a n d c y s t a t i n C m u c h more t i g h t l y t h a n 
c a t h e p s i n Β a n d w o u l d n o t be d e t e c t a b l e as a c t i v e enzyme (It/Κι o f 3 χ 10 5 
w i t h k i n i n o g e n a n d 2 χ 1 0 4 w i t h c y s t a t i n C). S u r p r i s i n g l y , o n l y t r aces o f 
c a t h e p s i n Β a c t i v i t y h a v e been f o u n d a s s o c i a t e d w i t h 0L2M whereas p a p a i n is 
e n t r a p p e d r e a d i l y [ 2 ] . 
Pathob iochemica l r e l e v a n c e of c a theps in Β 
I t i s t e m p t i n g t o s p e c u l a t e t h a t i n c r e a s e d c a t h e p s i n B - l i k e a c t i v i t y i s d i r e c t l y 
i n v o l v e d i n p a t h o m e c h a n i s m s l e a d i n g t o t r a u m a - r e l a t e d o r gan f a i l u r e , such as 
ARDS, o r p e r s i s t e n t p e r i t o n i t i s . As f a r as d a t a are a v a i l a b l e , i s o l a t e d 
c a t h e p s i n Β i s n o t v e r y a c t i v e on p r o t e i n s u b s t r a t e s [ 20 ] , b u t t h i s may be 
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d i f f e r e n t f o r c a t h e p s i n Β p r e c u r s o r s w h i c h h a v e been f o u n d i n s p u t u m [21} 
a n d i n t u m o r s [22 ] . The p r o t e o l y t i c p o t e n t i a l o f t h e r e l e a s e d c a t h e p s i n B - l i k e 
a c t i v i t y f o r t h e c l eavage o f p h y s i o l o g i c a l l y i m p o r t a n t p r o t e i n s needs t o be 
i n v e s t i g a t e d i n more d e t a i l . Bes ides i t s own p r o t e o l y t i c a c t i v i t y , c a t h e p s i n Β 
may be e n v i s a g e d as an i n d i c a t o r f o r t h e s i m u l t a n e o u s r e l e a s e o f o t h e r 
c y s t e i n e p r o t e i n a s e s . U n l i k e c a t h e p s i n B, c a t h e p s i n L has been s h o w n t o 
c l eave e l a s t i n [23] a n d t o i n a c t i v a t e αιΡΙ [ 2 4 ] . The d e c r eas ed i n h i b i t o r y 
c a p a c i t y obse r v ed i n b l o o d p l a sma o f p a t i e n t s a n d i n B A L F m a y e n h a n c e t h e 
h a r m f u l e f f e c t s o f r e l eased l y s o s o m a l c y s t e i n e p r o t e i n a s e s . 
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